Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into ...

NEW HAVEN, Conn. - Rallybio Corporation (NASDAQ: RLYB), a clinical-stage biotechnology company with a market capitalization of $32.36 million, has initiated a Phase 2 clinical trial for RLYB212, a ...

Neonatal alloimmune neutropenia (NAN) is a condition where a newborn's neutrophils, a type of white blood cell crucial for fighting infections, are destroyed by antibodies produced in response to ...

Following Johnson & Johnson’s (J&J) recent US Food and Drug Administration (FDA) fast track designation of nipocalimab for the reduction of foetal and neonatal alloimmune thrombocytopenia (FNAIT ...

[2] Platelet destruction in the neonate can be from an immune response to antibodies in the neonatal circulation. In the following sections, autoimmune and alloimmune thrombocytopenia will be ...

In preterm babies, plasmatic coagulation becomes subject to a tendency to hemorrhage, and neonatal alloimmune thrombocytopenia (NAIT) may be present (3). Both should be considered on obstetric ...

Rallybio (RLYB) announced that the first participant has been dosed in the Phase 2 trial investigating RLYB212 in pregnant women at higher risk ...